These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 32757044)

  • 1. Comparative cardiovascular safety of strontium ranelate and bisphosphonates: a multi-database study in 5 EU countries by the EU-ADR Alliance.
    Ali MS; Berencsi K; Marinier K; Deltour N; Perez-Guthann S; Pedersen L; Rijnbeek P; Lapi F; Simonetti M; Reyes C; Van der Lei J; Sturkenboom M; Prieto-Alhambra D
    Osteoporos Int; 2020 Dec; 31(12):2425-2438. PubMed ID: 32757044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of risk minimisation measures on the use of strontium ranelate in Europe: a multi-national cohort study in 5 EU countries by the EU-ADR Alliance.
    Berencsi K; Sami A; Ali MS; Marinier K; Deltour N; Perez-Gutthann S; Pedersen L; Rijnbeek P; Van der Lei J; Lapi F; Simonetti M; Reyes C; Sturkenboom MCJM; Prieto-Alhambra D
    Osteoporos Int; 2020 Apr; 31(4):721-755. PubMed ID: 31696274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of acute myocardial infarction for anti-osteoporosis drugs in primary care: a meta-analysis of propensity-matched cohort findings from the UK Clinical Practice Research Database and the Catalan SIDIAP Database.
    Khalid S; Calderon-Larranaga S; Sami A; Hawley S; Judge A; Arden N; Van Staa TP; Cooper C; Abrahamsen B; Javaid MK; Prieto-Alhambra D
    Osteoporos Int; 2022 Jul; 33(7):1579-1589. PubMed ID: 35138412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ischaemic cardiac events and use of strontium ranelate in postmenopausal osteoporosis: a nested case-control study in the CPRD.
    Cooper C; Fox KM; Borer JS
    Osteoporos Int; 2014 Feb; 25(2):737-45. PubMed ID: 24322476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of venous thromboembolism among users of different anti-osteoporosis drugs: a population-based cohort analysis including over 200,000 participants from Spain and the UK.
    Martín-Merino E; Petersen I; Hawley S; Álvarez-Gutierrez A; Khalid S; Llorente-Garcia A; Delmestri A; Javaid MK; Van Staa TP; Judge A; Cooper C; Prieto-Alhambra D
    Osteoporos Int; 2018 Feb; 29(2):467-478. PubMed ID: 29199359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of oral bisphosphonates and risk of venous thromboembolism: a population-based case-control study.
    Lamberg AL; Horvath-Puho E; Christensen S; Sørensen HT
    Osteoporos Int; 2010 Nov; 21(11):1911-7. PubMed ID: 19997902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England.
    Osborne V; Layton D; Perrio M; Wilton L; Shakir SA
    Drug Saf; 2010 Jul; 33(7):579-91. PubMed ID: 20553059
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of cardiac valvulopathy with use of bisphosphonates: a population-based, multi-country case-control study.
    Coloma PM; de Ridder M; Bezemer I; Herings RM; Gini R; Pecchioli S; Scotti L; Rijnbeek P; Mosseveld M; van der Lei J; Trifirò G; Sturkenboom M;
    Osteoporos Int; 2016 May; 27(5):1857-67. PubMed ID: 26694594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac concerns associated with strontium ranelate.
    Reginster JY
    Expert Opin Drug Saf; 2014 Sep; 13(9):1209-13. PubMed ID: 25020233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of strontium ranelate and risk of acute coronary syndrome: cohort study.
    Svanström H; Pasternak B; Hviid A
    Ann Rheum Dis; 2014 Jun; 73(6):1037-43. PubMed ID: 24651624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate.
    Abrahamsen B; Grove EL; Vestergaard P
    Osteoporos Int; 2014 Feb; 25(2):757-62. PubMed ID: 24322475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
    Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
    Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of strontium ranelate on markers of cardiovascular risk in postmenopausal osteoporotic women.
    Atteritano M; Catalano A; Santoro D; Lasco A; Benvenga S
    Endocrine; 2016 Jul; 53(1):305-12. PubMed ID: 26304851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strontium ranelate for preventing and treating postmenopausal osteoporosis.
    O'Donnell S; Cranney A; Wells GA; Adachi JD; Reginster JY
    Cochrane Database Syst Rev; 2006 Jul; (3):CD005326. PubMed ID: 16856092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of acute myocardial infarction among new users of bisphosphonates: a nested case-control study.
    Mazzucchelli R; Rodríguez-Martín S; García-Vadillo A; Crespí-Villarías N; Gil M; Rodriguez-Miguel A; Barreira D; Garcia-Lledó A; de Abajo FJ
    Osteoporos Int; 2020 Dec; 31(12):2403-2412. PubMed ID: 32662036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. One and two-year persistence with different anti-osteoporosis medications: a retrospective cohort study.
    Reyes C; Tebe C; Martinez-Laguna D; Ali MS; Soria-Castro A; Carbonell C; Prieto-Alhambra D
    Osteoporos Int; 2017 Oct; 28(10):2997-3004. PubMed ID: 28714038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strontium ranelate treatment in a postmenopausal woman with osteonecrosis of the jaw after long-term oral bisphosphonate administration: a case report.
    Pan WL; Chen PL; Lin CY; Pan YC; Ju YR; Chan CP; Hsu RW
    Clin Interv Aging; 2017; 12():1089-1093. PubMed ID: 28744112
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral Bisphosphonates and Upper Gastrointestinal Cancer Risks in Asians with Osteoporosis: A Nested Case-Control Study Using National Retrospective Cohort Sample Data from Korea.
    Jung SY; Sohn HS; Park EJ; Suh HS; Park JW; Kwon JW
    PLoS One; 2016; 11(3):e0150531. PubMed ID: 26937968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women.
    Stevenson M; Davis S; Lloyd-Jones M; Beverley C
    Health Technol Assess; 2007 Feb; 11(4):1-134. PubMed ID: 17280622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.